Infirst Healthcare to promote pediatric cough-cold brand Dr. Cocoa in U.S. market
LONDON — Infirst Healthcare earlier this month secured the rights to market Dr. Cocoa, an award-winning cocoa-flavored pediatric cough remedy.
“Many cough treatments have deficiencies in their efficacy, safety and compliance profiles and Infirst Healthcare is committed to finding solutions that address these issues," Manfred Scheske, Infirst CEO said. "Introducing compliance optimized pediatric products that taste better to children is a step in this direction. We are excited about the start of our U.S. operations in the pediatric OTC market.
Dr. Cocoa was named "Best Product" at the 2013 US Cough & Cold ECRM conference, an award sponsored by DSN. The patent protected line of products has been formulated with real chocolate in order to improve compliance for better symptom relief.
The Dr. Cocoa brand is brought to life through the Dr. Cocoa Owl character which depicts the family doctor speaking to children and parents in a knowledgeable and credible way, and will be used throughout all marketing and communications activity, the company noted.
With this agreement, Infirst Healthcare now holds the exclusive global rights for the use of cocoa and chocolate in cough products. Infirst Healthcare will be building its U.S. presence and preparing for the launch of Dr. Cocoa in 2014. Infirst Healthcare will be represented in the U.S. by Advantage Consumer Healthcare.
Inergetics partners with the Podiatree Co. on new nerve health support supplement
NEWARK, N.J. — Inergetics and the Podiatree Co. on Tuesday launched Intrinsix, a podiatry-exclusive nerve health support supplement enriched with calcium and vitamin D.
Developed alongside pharmacist, Robert Graci, Inergetics has created a unique formula to support healthy nerve function and specifically help diabetic patients who experience nerve-related symptoms in their extremities, which include tingling, pain, burning and loss of sensation, the company stated.
"With approximately 15,000 podiatrists practicing in the U.S., we are taking a direct sales approach to help them support the ever-increasing proportion of the population suffering with diabetes," Inergetics CEO Mike James said. "Intrinsix is a great addition to the Inergetics family and we look forward to continuing our work with The Podiatree Company to advance foot care for the benefit of patients."
"As a company dedicated to the podiatry specialty market, we take pride in being able to provide our physician partners with unique and efficacious specialty products to meet their patients’ needs," Graci said.
Intrinsix contains a unique blend of alpha lipoic acid, benfotiamine, calcium and vitamins B6, B12 and D. The formula is safe for patients with strict dietary restrictions, including vegetarians and those with sugar-free, sodium-free and starch-free diets, Inergetics noted.
Pfizer acquires low-dose aspirin brand in Poland
NEW YORK — Pfizer on Monday announced that a wholly-owned Polish subsidiary of Pfizer has acquired the rights to Polocard, a low-dose aspirin (acidum acetylsalicylicum), and the leading over-the-counter brand for heart attack prevention in Poland, from ZF Polpharma SA.
"Polocard is a top OTC brand in Poland, and its acquisition will enhance our Consumer Healthcare portfolio and overall position in this key market," said Paul Sturman, president, Pfizer Consumer Healthcare. "We continue to focus on strategic opportunities that will expand our portfolio of leading brands, develop capabilities in high-growth categories and extend our global reach."
The acquisition of Polocard marks the latest of several investments by Pfizer in its Consumer Healthcare business over the last 24 months. Other notable transactions include the exclusive global license agreement with AstraZeneca for the OTC rights for Nexium (esomeprazole magnesium) and the acquisitions of Alacer, maker and distributor of Emergen-C products, one of the largest-selling branded Vitamin C lines in the United States, and Ferrosan’s Consumer Healthcare business, which broadened the unit’s dietary supplements portfolio as well as its geographic footprint in the Nordics, Russia and Central and Eastern Europe.
The financial terms of the Polocard deal were not disclosed.